Abstract Details
| Faye McKenna
					(UCSF) PRESENTER | No disclosure on file | 
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Shubir Dutt | Mr. Dutt has nothing to disclose. | 
| Jon Elofson | No disclosure on file | 
| John Kornak | No disclosure on file | 
| Bruce L. Miller, MD, FAAN (University of California, San Francisco) | Dr. Miller has nothing to disclose. | 
| Howard J. Rosen, MD (UCSF) | Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |